

Yasushi Honda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3173184/publications.pdf>

Version: 2024-02-01

30
papers

1,206
citations

623188

14
h-index

500791

28
g-index

32
all docs

32
docs citations

32
times ranked

1611
citing authors

#	ARTICLE	IF	CITATIONS
1	Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 908-917.e11.	2.4	57
2	Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 186-195.	3.6	9
3	Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. <i>Hepatology Communications</i> , 2022, 6, 2273-2285.	2.0	17
4	Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study. <i>BMJ Open</i> , 2022, 12, e060335.	0.8	2
5	Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. <i>World Journal of Gastroenterology</i> , 2021, 27, 609-623.	1.4	24
6	Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001990.	1.2	53
7	Vitamin B6 efficacy in the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, single-center trial. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2021, 68, 181-186.	0.6	13
8	Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2275-2284.	1.4	26
9	What considerations are there for the pharmacotherapeutic management of nonalcoholic steatohepatitis?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1217-1220.	0.9	4
10	Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake. <i>Oncologist</i> , 2021, 26, e1862-e1869.	1.9	2
11	Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. <i>Journal of Gastroenterology</i> , 2021, 56, 1022-1032.	2.3	49
12	Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 996-1007.	3.7	22
13	Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4939.	1.8	8
14	Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs. <i>Diagnostics</i> , 2020, 10, 912.	1.3	15
15	Advances in ultrasound elastography for nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 521-533.	0.6	17
16	Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 535-548.	0.6	9
17	Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease. <i>BMJ Open</i> , 2020, 10, e037961.	0.8	6
18	Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype. <i>Frontiers in Oncology</i> , 2020, 10, 555963.	1.3	1

#	ARTICLE	IF	CITATIONS
19	Metabolomic/lipidomicâ€based analysis of plasma to diagnose hepatocellular ballooning in patients with nonâ€alcoholic fatty liver disease: A multicenter study. <i>Hepatology Research</i> , 2020, 50, 955-965.	1.8	12
20	Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4039.	1.8	35
21	Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100516.	0.5	11
22	A case of hepatitis B virus reactivation with hemochromatosis after allogeneic bone marrow transplantation for acute myeloid leukemia. <i>Acta Hepatologica Japonica</i> , 2020, 61, 504-512.	0.0	0
23	Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with nonâ€alcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 1136-1146.	1.8	24
24	Assessment of 10â€year changes in liver stiffness using vibrationâ€controlled transient elastography in nonâ€alcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 872-880.	1.8	19
25	Distribution of liver stiffness in nonâ€alcoholic fatty liver disease with higher fibrosisâ€4 index than low cutâ€off index. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1411-1416.	1.4	6
26	Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. <i>Contemporary Clinical Trials</i> , 2018, 69, 40-47.	0.8	4
27	<i>Wisteria floribunda</i> agglutininâ€positive Macâ€2â€bindingâ€ protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with nonâ€alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1795-1803.	1.4	34
28	Magnetic resonance elastography increases usefulness and safety of nonâ€invasive screening for esophageal varices. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 2022-2028.	1.4	30
29	Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. <i>Gastroenterology</i> , 2016, 150, 626-637.e7.	0.6	628
30	Nonâ€alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1009-1014.	1.4	69